Type 2 diabetes. Type 2 diabetes mellitus
Conditions
Interventions
Intervention group: The administration of 1.5 x 10^6 mesenchymal stem cells derived from umbilical cord is to be conducted intravenously in three doses, spaced four weeks apart. (In the initial inject
Sponsors
Mashhad University of Medical Sciences
Eligibility
Sex/Gender
All
Age
20 Years to 65 Years
Inclusion criteria
Inclusion criteria: 35 kg/m2 = BMI = 24 kg/m2 10% = HbA1c= 8% The fasting C-peptide level is greater than or equal to 1 ng/mL. A stable dose of exogenous insulin between 0.5 and 1.5 U/kg/day for a minimum of 3 months prior to treatment. Not receiving biological drugs Patients who are receiving insulin analogs and have not been administered pioglitazone in the past three months.
Exclusion criteria
Exclusion criteria: Concurrent diagnosis of other chronic underlying diseases. Diabetic coma. Hyperosmolar syndrome. Renal failure with GFR < 60 ml/min. Myocardial or cerebral infarction within three months prior to treatment. Concurrent participation in other clinical trials. Failure to complete the informed consent form.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Investigating inflammatory factors. Timepoint: Six months after the intervention. Method of measurement: Gene expression levels measured by the real-time PCR method. | — |
Secondary
| Measure | Time frame |
|---|---|
| HbA1c level, the patient's need for insulin, blood glucose level, beta cell function (measured by the level of C-peptide), CBC? ESR. Timepoint: Six months after the intervention. Method of measurement: Biochemical and hematological laboratory tests.;Expression of inflammatory genes IKB-a, TNF-a, IL-6, and IL-1. Timepoint: Six months after the intervention. Method of measurement: Gene expression levels measured by the Real-time PCR method. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHamid reza Rahimi
Mashhad University of Medical Sciences
Outcome results
None listed